Orrick Advises Third Rock Ventures on Investment in CARGO Therapeutics
1 minute read | March.02.2023
The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.
Client Results
Orrick Advises SFJ Pharmaceuticals on Acquisition of Bentracimab Assets from PhaseBio
January.18.2023
Orrick advised SFJ on its acquisition of assets related to the drug Bentracimab from PhaseBio.
Orrick Advises Ipsen on Acquisition of Liver Disease Treatment Innovator Albireo
1 minute read | January.09.2023
Orrick is advising Ipsen (Euronext: IPN: ADR: IPSEY) on its acquisition of Albireo Pharma Inc (NASDAQ: ALBO), a leading innovator in bile-acid ...
Orrick Advises Catalyst Biosciences in Reverse Merger with GNI Group
1 minute read | December.28.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. in its acquisition of the F351 program, a ...
Orrick Advises BioAtla on $65 Million Underwritten Offering of its Common Stock
1 minute read | November.11.2022
Orrick advised clinical-stage biotech company BioAtla on the sale of 9,745,128 shares of its common stock in an underwritten offering.
Orrick Advises Qualifacts on Its Acquisition of OnCall Health
November.03.2022
Congratulations to our client Qualifacts on its acquisition of OnCall Health, a telehealth, patient portal and client engagement technology provider.
Orrick Advises Bayer on Partnership with Ginkgo Bioworks
October.17.2022
Orrick advised Bayer on its three-year strategic partnership with biotech company Ginkgo Bioworks to accelerate the research and development of ...
Orrick Advises Kain Capital on Investment in MY DR NOW
September.01.2022
The investment marks the first time MY DR NOW has received external capital.
Orrick Advises on Joint Acquisition and Combination of Kedrion and BPL
September.01.2022
After a long and complex prenotification phase before the European Commission, Orrick obtained an early unconditional clearance of the transaction.
Orrick Advises Sosei Heptares on Multi-Target Collaboration with AbbVie
August.03.2022
We advised Sosei Heptares, an international biopharmaceutical company and world-leader in G protein-coupled receptor (GPCR) focused structure-based ...
Orrick Advises Medical Microinstruments on $75 Million Series B Round
July.25.2022
Medical Microinstruments is a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery.
Orrick Advises MorphoSys on Equity Participation Transaction with HIBio
July.08.2022
Orrick advised German biopharmaceutical company MorphoSys on its equity participation transaction with biotech company Human Immunology Biosciences
Insights
6 Things to Know About Washington’s My Health My Data Law
by Thora Johnson, Kyle Kessler, Michaela Frai and Alyssa Wolfington
8 minute read | May.09.2023
The state of Washington recently enacted My Health My Data (“MHMD”), a game-changing new consumer privacy law focused on health data.
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2023
26 minute read | April.25.2023
This edition of Orrick’s life sciences publication series reviews key trends of venture investment in the life sciences industry during Q1 2023.
UK: Biometric Technologies – An Early Warning and Picture of the Way Forwards from the ICO
by Kelly Hagedorn and Anna O'Kelly
9 minute read | March.23.2023
Kelly Hagedorn and Anna O'Kelly explore the ICO's perspective on biometric technologies, their potential, risks, and regulatory avenues for the future
What Healthcare Companies Need to Know and Do About Ad Tracking Technologies
by Thora Johnson, Kyle Kessler, Hannah Levin and Alyssa Wolfington
6 minute read | March.14.2023
Healthcare companies track visitors to websites and mobile apps with third-party technologies like cookies and pixels, but that widespread practice ...
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2023
16 minute read | February.14.2023
Venture Funding and Tech Trends in Mental Health
DAOs Might Be Cure for Biotech Startups and New Drug Development
by Joseph Perkins and Stephen Thau
January.17.2023
Joseph Perkins and Stephen Thau explain how early-stage biotech startups can use DAOs to provide an alternative to traditional sources of capital.
Additional Considerations on IP Due Diligence for Prospective Investors of Emerging Life Sciences Companies
by Gargi Talukder, Jennifer Ng, Jessica Stern and Alex Straughn
December.15.2022
Following our first article on IP due diligence considerations for prospective investors of emerging life sciences companies, we’re taking an ...
Intellectual Property Due Diligence Considerations for Prospective Investors of Emerging Life Sciences Companies
by Gargi Talukder, Jennifer Ng, Jessica Stern and Alex Straughn
December.01.2022
How the right level of IP due diligence can help inform investment decisions in the life sciences arena.
ESG Drivers and Best Practices for Life Sciences Companies Webinar
November.30.2022
ESG factors are increasingly important in the life sciences. Managing ESG risks and opportunities can be an important source of long-term value.
OLNS#10: University Entrepreneurship & Spin-offs in Germany – Set-up / IP / Financing and Much More
November.15.2022
German universities increasingly are becoming entrepreneurial hotbeds, though university spin-offs face unique challenges.
Global Authorities Ramp Up Medical Device Cybersecurity Expectations: What Medical Device Companies Need to Know
by Thora Johnson, Hannah Levin, Cameron Carr and Michaela Frai
October.25.2022
The last year has seen a multijurisdictional regulatory push for increased cybersecurity standards for medical devices. Here's what you need to know.
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2022
23 minute read | October.24.2022
Leveraging Non-Dilutive Financing For Drug Development and Favorably Licensing Developed Products as a Global Health Model
News
Orrick Expands International Arbitration Team in New York
2 minute read | February.09.2023
Hagit Muriel Elul joins our international arbitration practice in New York from Hughes Hubbard.
Orrick Boosts Life Sciences Platform With 4-Partner Powerhouse IP Litigation Team
4 minute read | November.15.2022
Welcome to David Gindler, Gary Frischling, Lauren Drake and John Yu, who join us as partners in Southern California.
FTC Attorney Adviser Anna Aryankalayil to Join Orrick’s DC Antitrust Team
November.07.2022
Anna Aryankalayil will join the firm Nov. 14 as a partner in our Antitrust and Competition practice.
Orrick Life Sciences Team Recognized at 2022 LMG Life Sciences Awards
September.09.2022
Congratulations to all of the members of the Orrick Life Sciences team recognized at this year’s LMG Life Sciences Awards.
American Lawyer Again Names Josh Rosenkranz “Litigator of the Year” Finalist
August.08.2022
American Lawyer has twice before recognized Josh as Litigator of Year.
Life Sciences Highlights for H1 2022
August.01.2022
In the first half of 2022, our teams advised on 80 mergers, acquisitions, VC financings and other transactions in the Life Sciences sector.
Orrick’s Gregg Griner Named Life Sciences Go-To Lawyer
May.31.2022
Congratulations to Orrick partner Gregg Griner on being recognized as a Go-To Lawyer for Healthcare and Life Sciences by Massachusetts Lawyers Weekly.
Orrick Continues Growth of Life Sciences & Tech Team
February.22.2022
Welcome to Tony Chan who joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors.
Orrick Expands Antitrust Team with Two DC Hires
January.03.2022
Eileen Cole and Craig Falls join the firm as partners in our Antitrust and Competition practice.
Orrick Adds Life Sciences Adviser and Former Prosecutor to White Collar Team
October.11.2021
Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.
Events
Events
2022 TechGC Global Summit
Thora Johnson will be leading a breakout topic session at the 2022 TechGC Global Summit.
Events
It Is Not Just HIPAA Anymore.
The Implication of State Consumer Data Privacy Laws and the FTC Breach Notification Law for Health Data.
Events
Reception at the 2023 J.P. Morgan Healthcare Conference
Orrick and Pitchbook are co-hosting a reception during the J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 from 6pm-9pm in San Francisco. This should be an excellent gathering of a curated list of venture-backed life sciences companies, VC and PE investors, corporates, CVCs and ...
Events
HCCA's 27th Annual Compliance Institute: It’s De-identified, or Is It?
Thora Johnson will lead an “It’s De-identified, or Is It?,” panel discussion at the 27th Annual Compliance Institute hosted by the Health Care Compliance Association (HCCA).
Events
The Health Care Compliance Association (HCAA) Research Compliance Conference: It’s Not Research, It’s Quality Improvement
Thora Johnson, a partner in Orrick’s Cyber, Privacy & Data Innovation Group, will lead the session “It’s Not Research, It’s Quality Improvement,” at the Health Care Compliance Association (HCAA) Research Compliance Conference.
Events
Privacy + Security Forum Spring Academy
Heather Sussman and Shannon Yavorsky led two individual panels during the Privacy + Security Forum Spring Academy hosted by the Privacy Security Academy.
Events
31st Annual National Virtual HIPAA Summit: State Consumer Data Privacy Laws and the FTC Breach Notification Law & Responding to OCR Document Request
Thora Johnson, a partner in Orrick's Cyber, Privacy & Data Innovation Group, will leading two panels at the 31st Annual National Health Insurance Portability and Accountability Act (HIPAA) Summit.